Halozyme Therapeutics Inc. (NASDAQ: HALO) closed the day trading at $40.22 down -0.40% from the previous closing price of $40.38. In other words, the price has decreased by -$0.16 from its previous closing price. On the day, 925858 shares were traded.
Ratios:
For a better understanding of HALO, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.21 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.69. For the most recent quarter (mrq), Quick Ratio is recorded 5.50 and its Current Ratio is at 6.64. In the meantime, Its Debt-to-Equity ratio is 18.27 whereas as Long-Term Debt/Eq ratio is at 17.89.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on February 29, 2024, initiated with a Outperform rating and assigned the stock a target price of $54.
On July 24, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $61.
Goldman Downgraded its Buy to Neutral on July 24, 2023, whereas the target price for the stock was revised from $43 to $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 13 ’24 when LaBarre Michael J. sold 10,000 shares for $42.27 per share. The transaction valued at 422,730 led to the insider holds 156,558 shares of the business.
LaBarre Michael J. sold 10,000 shares of HALO for $416,370 on Mar 12 ’24. The SVP, CHIEF TECHNICAL OFFICER now owns 156,558 shares after completing the transaction at $41.64 per share. On Feb 28 ’24, another insider, LaBarre Michael J., who serves as the SVP, CHIEF TECHNICAL OFFICER of the company, sold 10,000 shares for $39.55 each. As a result, the insider received 395,463 and left with 156,558 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 5.11B and an Enterprise Value of 6.27B. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 19.07, and their Forward P/E ratio for the next fiscal year is 9.06. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.76. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.16 while its Price-to-Book (P/B) ratio in mrq is 60.84. Its current Enterprise Value per Revenue stands at 7.57 whereas that against EBITDA is 13.88.
Stock Price History:
Over the past 52 weeks, HALO has reached a high of $45.00, while it has fallen to a 52-week low of $29.85. The 50-Day Moving Average of the stock is 37.39, while the 200-Day Moving Average is calculated to be 38.29.
Shares Statistics:
Over the past 3-months, HALO traded about 1.38M shares per day on average, while over the past 10 days, HALO traded about 1.08M shares per day. A total of 126.77M shares are outstanding, with a floating share count of 125.68M. Insiders hold about 1.08% of the company’s shares, while institutions hold 98.70% stake in the company. Shares short for HALO as of Feb 29, 2024 were 8.08M with a Short Ratio of 5.87, compared to 7.64M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.37% and a Short% of Float of 7.60%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of $0.76 for the current quarter, with a high estimate of $0.83 and a low estimate of $0.69, while EPS last year was $0.47. The consensus estimate for the next quarter is $0.79, with high estimates of $0.86 and low estimates of $0.73.
Analysts are recommending an EPS of between $3.77 and $3.61 for the fiscal current year, implying an average EPS of $3.68. EPS for the following year is $4.58, with 5 analysts recommending between $4.67 and $4.41.
Revenue Estimates
9 analysts predict $212.15M in revenue for the current quarter. It ranges from a high estimate of $259.4M to a low estimate of $180.72M. As of the current estimate, Halozyme Therapeutics Inc.’s year-ago sales were $175.51M, an estimated increase of 20.90% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $217.56M, an increase of 8.80% less than the figure of $20.90% in the same quarter last year. There is a high estimate of $230.34M for the next quarter, whereas the lowest estimate is $203.8M.
A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $967.58M, while the lowest revenue estimate was $937M, resulting in an average revenue estimate of $954.58M. In the same quarter a year ago, actual revenue was $829.25M, up 15.10% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $1.09B in the next fiscal year. The high estimate is $1.12B and the low estimate is $1.07B. The average revenue growth estimate for next year is up 13.80% from the average revenue estimate for this year.
